Last reviewed · How we verify
129 Xenon
At a glance
| Generic name | 129 Xenon |
|---|---|
| Also known as | 129-Xe |
| Sponsor | Dr. Grace Parraga |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Dissolved Phase HXe-129 MRI: A Novel Biomarker to Quantify Pulmonary Pathology (PHASE2, PHASE3)
- 129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH) (PHASE2)
- Xenon MRI and Progressive ILD (PHASE2)
- 129 Xenon Imaging in Patients Treated With Sotatercept (PHASE2)
- Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults (PHASE1, PHASE2)
- Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease (PHASE1, PHASE2)
- Hyperpolarized 129-Xenon Imaging in Adult Hematopoietic Cell Transplant Recipients With Pulmonary Impairment
- 129Xe MRI in Pediatric Population With BPD (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 129 Xenon CI brief — competitive landscape report
- 129 Xenon updates RSS · CI watch RSS
- Dr. Grace Parraga portfolio CI